Thomas Greenwell
Memphis, TNNPI 1013913474
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $91,597 of the $98,089 with a category attached, or 93.4%. Organon accounts for 72.0% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2021 at $28,867 and has fallen 89.1% since, to $3,150 in 2025.
Across 285 payments — averaging $344.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$71K
- Merck$24K
- AbbVie$1K
- Amgen$416
- Mayne Pharma Commercial LLC$327
- Hologic Sales And Service, LLC$221
- plus $1K from 25 others
What the payments were for
- Speaking & faculty fees$91,59793%
- Travel & lodging$2,6353%
- Food & beverage$3,8574%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 92 | $70,620 |
| Merck | 36 | $23,970 |
| AbbVie(2 entities) | 48 | $1,052 |
| Amgen | 10 | $416 |
| Mayne Pharma Commercial LLC | 9 | $327 |
| Hologic Sales And Service, LLC | 12 | $221 |
| Myovant Sciences Inc. | 16 | $203 |
| Daiichi Sankyo Inc. | 10 | $169 |
| Boston Scientific | 2 | $137 |
| Novo Nordisk | 8 | $132 |
| Astellas Pharma US Inc | 1 | $119 |
| Biohaven Pharmaceuticals, Inc. | 1 | $114 |
| Bayer | 5 | $94 |
| Sumitomo Pharma America, Inc. | 4 | $60 |
| Mylan Pharmaceuticals Inc. | 4 | $54 |
| Scynexis, Inc. | 3 | $46 |
| Therapeuticsmd, Inc. | 3 | $40 |
| Avion Pharmaceuticals | 3 | $35 |
| Coopersurgical, Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Pfizer | 2 | $29 |
| Agile Therapeutics, Inc. | 2 | $28 |
| Evofem Biosciences, Inc. | 2 | $28 |
| Convatec Inc. | 1 | $25 |
| Channel Medsystems, Inc. | 1 | $19 |
| BD | 1 | $18 |
| Minerva Surgical, Inc | 1 | $14 |
| Medtronic | 1 | $14 |
| Bausch Health US, LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$92,957
- Prolia$326
- UBRELVY$233
- Bead Block 900-1200$125
- Veozah$119
- NEXTSTELLIS$114
- NURTEC ODT$114
- Orilissa$110
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 11 | $2,957 |
| Estradiol | 14 | $291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $29 | $2,95711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Tennesseeon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.